COLUMBUS, Ohio, July 31 /PRNewswire/ -- PharmaForce, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension, USP, a generic version of Schering Corporation's Celestone(R) Soluspan(R).
PharmaForce's product is manufactured in the USA and is marketed in a 6 mg/mL (3 mg base betamethasone/mL; 3 mg/mL betamethasone acetate), 5mL vial dosage form.
Shipment of this product has commenced and is available through wholesalers and distributors.
"PharmaForce is proud to be providing the healthcare community with this first generic equivalent of Celestone(R) Soluspan(R)," said Nicholas Uchyn, Vice President of Sales.
About PharmaForce, Inc.
PharmaForce, Inc., founded in 1999, is a privately held specialty pharmaceutical company that develops, manufactures, and distributes pharmaceutical products. PharmaForce specializes in injectable, ophthalmic and otic products with more than 35 FDA approved medicines as well as over 30 additional products in development.
For more information about Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension and PharmaForce, Inc., please visit: www.pharmaforceinc.com.
Please refer to www.pharmaforceinc.com for full prescribing information.
Celestone(R) Soluspan(R) is a registered trademark of Schering Corporation.
Media Contact: Nicholas Uchyn Vice President of Sales PharmaForce, Inc. 960 Crupper Avenue Columbus, Ohio 43229 614/436-2222 email@example.com
|SOURCE PharmaForce, Inc.|
Copyright©2009 PR Newswire.
All rights reserved